Document is current
Any future updates will be listed below
-
Authors
Saffouri, George B.
Shields-Cutler, Robin R.
Chen, Jun
Yang, Yi
Lekatz, Heather R.
Hale, Vanessa L.
Cho, Janice M.
Battaglioli, Eric J.
Bhattarai, Yogesh
Thompson, Kevin J.
Kalari, Krishna K.
Behera, Gaurav
Berry, Jonathan C.
Peters, Stephanie A.
Patel, Robin
Schuetz, Audrey N.
Faith, Jeremiah J.
Camilleri, Michael
Sonnenburg, Justin L.
Farrugia, Gianrico
Swann, Jonathan R. https://orcid.org/0000-0002-6485-4529
Grover, Madhusudan https://orcid.org/0000-0001-5092-0831
Knights, Dan
Kashyap, Purna C. https://orcid.org/0000-0002-2851-2388
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK111850, DK114007, DK103911, DK115950)
Mayo Clinic Center for Individualized Medicine, Mayo Clinic, Rochester, MN
- License Information
-
More Information
Article History
Received: 4 October 2018
Accepted: 3 April 2019
First Online: 1 May 2019
Competing interests
: Robin Patel: Dr. Patel reports grants from CD Diagnostics, BioFire, Curetis, Merck, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, and The Medicines Company. Dr. Patel is or has been a consultant to Curetis, Specific Technologies, Selux Dx, GenMark Diagnostics, PathoQuest, Heraeus Medical and Genentech; monies are paid to Mayo Clinic. In addition, Dr. Patel has a patent on <i>Bordetella pertussis/parapertussis</i> PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued. Dr. Patel receives travel reimbursement from ASM and IDSA and an editor’s stipend from ASM and IDSA, and honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course. Michael Camilleri: Research support from Allergan to study effects of eluxadoline in IBS-diarrhea and bile acid malabsorption. Dan Knights: DK serves as CEO and holds equity in CoreBiome, a company involved in the commercialization of microbiome analysis. The University of Minnesota also has financial interests in CoreBiome under the terms of a license agreement with CoreBiome. These interests have been reviewed and managed by the University of Minnesota in accordance with its Conflict-of-Interest policies. Purna Kashyap: Advisory board uBiome, ad hoc advisory board Salix Pharmaceuticals. The remaining authors declare no competing interests.
